CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
Last Updated: Wednesday, April 23, 2025
This study investigated CART22-65s, a novel CD22-targeted CAR T-cell therapy, for children and adults with relapsed B-ALL after CD19 therapy. In 19 infused patients, the complete remission rate was 74%. The therapy demonstrated a favorable safety profile, suggesting its potential for treating this highly refractory leukemia.
Advertisement
News & Literature Highlights